Protara Launches $75 Million Public Offering to Fuel Clinical Trials
Protara Announces Proposed Public Offering
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara'), a clinical-stage company developing transformative...
Protara Therapeutics, Inc. has launched an underwritten public offering to raise $75 million. The Nasdaq-listed company (TARA) plans to share shares of its common stock or pre-funded warrants. The funds will primarily support clinical development of its lead candidate, TARA-002, alongside other programmes.
J.P. Morgan, TD Cowen, and Piper Sandler are managing the proposed offering as joint book-runners. The shares and warrants will be issued under an existing shelf registration statement on Form S-3, previously filed with the US Securities and Exchange Commission (SEC).
The success of the offering depends on market and regulatory conditions. If completed, the $75 million raised will advance Protara’s clinical pipeline, including TARA-002. Further details will be available once the SEC files the prospectus supplement and related documents.
